Pfizer innovation initiative invests $120M in 4 early-stage drugmakers


Pfizer’s innovation initiative has invested a total of $120 million into four clinical-stage biotech companies, the drugmaker announced Jan. 12.

The Pfizer Breakthrough Growth Initiative, launched in June, makes investments in biotech companies focusing on internal medicine, inflammation and immunology, oncology, rare diseases and vaccines. Pfizer plans to invest up to $500 million in biotechnology companies through the initiative.

Below are the first four companies Pfizer invested in:

  1. Bedford, Mass.-based Homology Medicines ($60 million)
  2. Cambridge, Mass.-based Trillium Therapeutics ($25 million)
  3. Cambridge, Mass.-based Vedanta Biosciences ($25 million)
  4. Vancouver-based ESSA Pharma ($10 million)

More articles on pharmacy:
Most successful vaccine rollouts in US: 4 state strategies
Utah pharmacy CEO charged for alleged illegal hydroxychloroquine importation
Health officials investigating death of Miami physician shortly after getting Pfizer vaccine

© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

Read More: Pfizer innovation initiative invests $120M in 4 early-stage drugmakers

Leave a reply